Jin‐ke Li

Meta‐analysis of the ability of mutational profiles on the cancer genome atlas to predict prognosis in endometrial carcinoma

AbstractBackgroundIn 2013, The Cancer Genome Atlas Research Network suggested that endometrial carcinoma patients may be reclassified into four molecular prognostic groups.ObjectiveTo compare survival of endometrial carcinoma patients with different mutational profiles.Search StrategyStudies reporting survival of endometrial carcinoma patients were identified through systematic searches of four databases.Selection CriteriaWe included relevant studies based on the literature type, data integrity and the methodological quality.Data Collection and AnalysisThe pooled survival data were compared among patients with different mutational profiles. Heterogeneity in the pooled data was assessed using the I2 statistic.Main ResultsData were meta‐analyzed from nine studies involving 4755 patients, who were classified into the following mutational profiles: p53abn, 745 patients (15.6%); MMRd, 1454 patients (30.6%); POLEmut, 351 patients (7.4%); and p53wt, 2205 patients (46.4%). Compared to the p53wt group, the p53abn group showed significantly worse overall survival (OS) (HR 2.31, 95% CI: 1.67–3.19), progression‐free survival (PFS) (HR 2.86, 95% CI: 1.45–5.64) and disease‐specific survival (HR 2.60, 95% CI: 1.41–4.79); and the MMRd group showed significantly worse OS (HR 1.30, 95% CI: 1.11–1.53) and PFS (HR 1.27, 95% CI: 1.01–1.59). The POLEmut group, in contrast, showed similar survival as the p53wt group.ConclusionsThe four mutational profiles for patients with endometrial carcinoma in the Cancer Genome Atlas for Endometrial Cancer are associated with worse to better survival in the trend: p53abn < MMRd < POLEmut ≈ p53wt. Mutational profiling may be useful for stratifying endometrial carcinoma patients by survival risk, which in turn may improve their management.

Pseudo‐pseudo Meigs syndrome in systemic lupus erythematosus misdiagnosed as pseudo‐Meigs' syndrome: A case report

AbstractSymptoms of pelvic masses, elevated serum CA125 levels, massive ascites, and pleural effusion in female patients are usually associated with malignancy. Some benign ovarian tumors or other nonmalignant tumors may also produce similar symptoms, called Meigs syndrome or pseudo‐Meigs' syndrome, which should be one of the differential diagnoses. However, there is an extremely rare form of SLE called pseudo‐pseudo Meigs syndrome (PPMS), which may also present with the above symptoms, but is not associated with any of the tumors. In this paper, we report a case of a 47‐year‐old woman who presented with abdominal distention. The patient was found to have elevated serum CA125 levels to 182.9 U/mL before the operation. Her PET‐CT suggested a large heterogeneous mass in the pelvis measuring 8.2 × 5.8 cm with a large amount of ascites. She was initially diagnosed with ovarian cancer and underwent exploratory laparotomy. Pathology of the surgical specimen revealed a uterine leiomyoma. Two months after discharge, the patient's ascites reappeared along with recurrent intestinal obstruction. After ascites and serological tests, she was eventually diagnosed with systemic lupus erythematosus and received systemic hormonal therapy.